Viridian Therapeutics' FY2024 earnings forecast raised to ($3.98) per share by Lifesci Capital analyst R. Katkhuda.

Viridian Therapeutics, Inc. (NASDAQ:VRDN) saw its FY2024 earnings forecast raised by Lifesci Capital analyst R. Katkhuda to ($3.98) per share from a previous estimate of ($5.72). The consensus estimate for Viridian's current full-year earnings is ($3.61) per share. Analysts at B. Riley also boosted their Q2 2024 EPS estimates to ($0.81) per share, up from their prior estimate of ($1.32).

May 15, 2024
3 Articles